Literature DB >> 34374761

Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes.

Jana L Jacobs1, William Bain2,3,4, Asma Naqvi1, Brittany Staines1, Priscila M S Castanha5, Haopu Yang2,6,7, Valerie F Boltz8, Simon Barratt-Boyes5, Ernesto T A Marques5, Stephanie L Mitchell9, Barbara Methé2,6, Tolani F Olonisakin2, Ghady Haidar1, Thomas W Burke10, Elizabeth Petzold10, Thomas Denny11, Chris W Woods10,11, Bryan J McVerry2, Janet S Lee2,3, Simon C Watkins12, Claudette M St Croix12, Alison Morris2,6, Mary F Kearney8, Mark S Ladinsky13, Pamela J Bjorkman13, Georgios D Kitsios2,3,6, John W Mellors1.   

Abstract

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA (vRNA) is detected in the bloodstream of some patients with coronavirus disease 2019 (COVID-19), but it is not clear whether this RNAemia reflects viremia (ie, virus particles) and how it relates to host immune responses and outcomes.
METHODS: SARS-CoV-2 vRNA was quantified in plasma samples from observational cohorts of 51 COVID-19 patients including 9 outpatients, 19 hospitalized (non-intensive care unit [ICU]), and 23 ICU patients. vRNA levels were compared with cross-sectional indices of COVID-19 severity and prospective clinical outcomes. We used multiple imaging methods to visualize virions in plasma.
RESULTS: SARS-CoV-2 vRNA was detected in plasma of 100%, 52.6%, and 11.1% of ICU, non-ICU, and outpatients, respectively. Virions were detected in plasma pellets using electron tomography and immunostaining. Plasma vRNA levels were significantly higher in ICU > non-ICU > outpatients (P < .0001); for inpatients, plasma vRNA levels were strongly associated with higher World Health Organization (WHO) score at admission (P = .01), maximum WHO score (P = .002), and discharge disposition (P = .004). A plasma vRNA level >6000 copies/mL was strongly associated with mortality (hazard ratio, 10.7). Levels of vRNA were significantly associated with several inflammatory biomarkers (P < .01) but not with plasma neutralizing antibody titers (P = .8).
CONCLUSIONS: Visualization of virus particles in plasma indicates that SARS-CoV-2 RNAemia is due, at least in part, to viremia. The levels of SARS-CoV-2 RNAemia correlate strongly with disease severity, patient outcome, and specific inflammatory biomarkers but not with neutralizing antibody titers.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  19 outcome; 2 RNAemia; 2 viremia; COVID; CoV; SARS

Mesh:

Substances:

Year:  2022        PMID: 34374761      PMCID: PMC9070832          DOI: 10.1093/cid/ciab686

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  43 in total

1.  A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy.

Authors:  Melissa A Tosiano; Jana L Jacobs; Kathleen A Shutt; Joshua C Cyktor; John W Mellors
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

2.  Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.

Authors:  Tomer Zohar; Carolin Loos; Stephanie Fischinger; Caroline Atyeo; Chuangqi Wang; Matthew D Slein; John Burke; Jingyou Yu; Jared Feldman; Blake Marie Hauser; Tim Caradonna; Aaron G Schmidt; Yongfei Cai; Hendrik Streeck; Edward T Ryan; Dan H Barouch; Richelle C Charles; Douglas A Lauffenburger; Galit Alter
Journal:  Cell       Date:  2020-11-03       Impact factor: 41.582

3.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.

Authors:  Jens D Lundgren; Birgit Grund; Christina E Barkauskas; Thomas L Holland; Robert L Gottlieb; Uriel Sandkovsky; Samuel M Brown; Kirk U Knowlton; Wesley H Self; D Clark Files; Mamta K Jain; Thomas Benfield; Michael E Bowdish; Bradley G Leshnower; Jason V Baker; Jens-Ulrik Jensen; Edward M Gardner; Adit A Ginde; Estelle S Harris; Isik S Johansen; Norman Markowitz; Michael A Matthay; Lars Østergaard; Christina C Chang; Victoria J Davey; Anna Goodman; Elizabeth S Higgs; Daniel D Murray; Thomas A Murray; Roger Paredes; Mahesh K B Parmar; Andrew N Phillips; Cavan Reilly; Shweta Sharma; Robin L Dewar; Marc Teitelbaum; Deborah Wentworth; Huyen Cao; Paul Klekotka; Abdel G Babiker; Annetine C Gelijns; Virginia L Kan; Mark N Polizzotto; B Taylor Thompson; H Clifford Lane; James D Neaton
Journal:  N Engl J Med       Date:  2020-12-22       Impact factor: 91.245

Review 4.  Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19.

Authors:  Isabelle Bernard; Daniel Limonta; Lara K Mahal; Tom C Hobman
Journal:  Viruses       Date:  2020-12-26       Impact factor: 5.048

5.  Dysregulated transcriptional responses to SARS-CoV-2 in the periphery.

Authors:  Micah T McClain; Florica J Constantine; Ricardo Henao; Yiling Liu; Ephraim L Tsalik; Thomas W Burke; Julie M Steinbrink; Elizabeth Petzold; Bradly P Nicholson; Robert Rolfe; Bryan D Kraft; Matthew S Kelly; Daniel R Saban; Chen Yu; Xiling Shen; Emily M Ko; Gregory D Sempowski; Thomas N Denny; Geoffrey S Ginsburg; Christopher W Woods
Journal:  Nat Commun       Date:  2021-02-17       Impact factor: 14.919

6.  Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.

Authors:  Katharina Röltgen; Abigail E Powell; Oliver F Wirz; Bryan A Stevens; Peter S Kim; Benjamin A Pinsky; Scott D Boyd; Catherine A Hogan; Javaria Najeeb; Molly Hunter; Hannah Wang; Malaya K Sahoo; ChunHong Huang; Fumiko Yamamoto; Monali Manohar; Justin Manalac; Ana R Otrelo-Cardoso; Tho D Pham; Arjun Rustagi; Angela J Rogers; Nigam H Shah; Catherine A Blish; Jennifer R Cochran; Theodore S Jardetzky; James L Zehnder; Taia T Wang; Balasubramanian Narasimhan; Saurabh Gombar; Robert Tibshirani; Kari C Nadeau
Journal:  Sci Immunol       Date:  2020-12-07

7.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2022-02-12       Impact factor: 79.321

8.  Neuropathological Features of Covid-19.

Authors:  Isaac H Solomon; Erica Normandin; Shamik Bhattacharyya; Shibani S Mukerji; Kiana Keller; Ahya S Ali; Gordon Adams; Jason L Hornick; Robert F Padera; Pardis Sabeti
Journal:  N Engl J Med       Date:  2020-06-12       Impact factor: 91.245

9.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

10.  SARS-CoV-2 viral load is associated with increased disease severity and mortality.

Authors:  Jesse Fajnzylber; James Regan; Kendyll Coxen; Heather Corry; Colline Wong; Alexandra Rosenthal; Daniel Worrall; Francoise Giguel; Alicja Piechocka-Trocha; Caroline Atyeo; Stephanie Fischinger; Andrew Chan; Keith T Flaherty; Kathryn Hall; Michael Dougan; Edward T Ryan; Elizabeth Gillespie; Rida Chishti; Yijia Li; Nikolaus Jilg; Dusan Hanidziar; Rebecca M Baron; Lindsey Baden; Athe M Tsibris; Katrina A Armstrong; Daniel R Kuritzkes; Galit Alter; Bruce D Walker; Xu Yu; Jonathan Z Li
Journal:  Nat Commun       Date:  2020-10-30       Impact factor: 14.919

View more
  30 in total

Review 1.  Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors.

Authors:  Roberta Rovito; Matteo Augello; Assaf Ben-Haim; Valeria Bono; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

2.  SARS-CoV-2 Viral Load in the Pulmonary Compartment of Critically Ill COVID-19 Patients Correlates with Viral Serum Load and Fatal Outcomes.

Authors:  Mario Ynga-Durand; Henrike Maaß; Marko Milošević; Fran Krstanović; Marina Pribanić Matešić; Stipan Jonjić; Alen Protić; Ilija Brizić; Alan Šustić; Luka Čičin-Šain
Journal:  Viruses       Date:  2022-06-14       Impact factor: 5.818

3.  Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019.

Authors:  Priscila M S Castanha; Dylan J Tuttle; Georgios D Kitsios; Jana L Jacobs; Ulisses Braga-Neto; Matthew Duespohl; Sanjay Rathod; Michelle M Marti; Sarah Wheeler; Asma Naqvi; Brittany Staines; John Mellors; Alison Morris; Bryan J McVerry; Faraaz Shah; Caitlin Schaefer; Bernard J C Macatangay; Barbara Methe; Christian A Fernandez; Simon M Barratt-Boyes; Donald Burke; Ernesto T A Marques
Journal:  J Infect Dis       Date:  2022-09-13       Impact factor: 7.759

4.  A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19.

Authors:  Stephen A Chitty; Sarah Mobbs; Brian S Rifkin; Steven W Stogner; Michael S Lewis; Jaime Betancourt; Jeffrey DellaVolpe; Fadi Abouzahr; Andrew M Wilhelm; Harold M Szerlip; Amay Parikh; Robert M Gaeta; Ian Rivera; Caroline Park; Benjamin Levi; George L Anesi; Karl C Alcover; Thomas B Arnold; Jeffrey T Howard; Kumar Sharma; Kathleen P Pratt; Ian J Stewart; Kevin K Chung
Journal:  Crit Care Explor       Date:  2022-03-25

Review 5.  ACE2 Shedding and the Role in COVID-19.

Authors:  Jieqiong Wang; Huiying Zhao; Youzhong An
Journal:  Front Cell Infect Microbiol       Date:  2022-01-14       Impact factor: 5.293

6.  Neutrophil Profiles of Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.

Authors:  Brittany P Boribong; Thomas J LaSalle; Yannic C Bartsch; Felix Ellett; Maggie E Loiselle; Jameson P Davis; Anna L K Gonye; Soroush Hajizadeh; Johannes Kreuzer; Shiv Pillai; Wilhelm Haas; Andrea Edlow; Alessio Fasano; Galit Alter; Daniel Irimia; Moshe Sade-Feldman; Lael M Yonker
Journal:  bioRxiv       Date:  2021-12-20

7.  Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19.

Authors:  Norma Maugeri; Rebecca De Lorenzo; Nicola Clementi; Roberta Antonia Diotti; Elena Criscuolo; Cosmo Godino; Cristina Tresoldi; Bio Angels For Covid-BioB Study Group; Chiara Bonini; Massimo Clementi; Nicasio Mancini; Fabio Ciceri; Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  J Thromb Haemost       Date:  2021-11-16       Impact factor: 16.036

8.  The Role of Von Willebrand Factor in the Pathogenesis of Pulmonary Vascular Thrombosis in COVID-19.

Authors:  Anastasiya S Babkina; Irina V Ostrova; Mikhail Ya Yadgarov; Artem N Kuzovlev; Andrey V Grechko; Alexey V Volkov; Arkady M Golubev
Journal:  Viruses       Date:  2022-01-21       Impact factor: 5.048

9.  Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study.

Authors:  Karl Hagman; Magnus Hedenstierna; Johan Rudling; Patrik Gille-Johnson; Berit Hammas; Malin Grabbe; Jan Jakobsson; Joakim Dillner; Johan Ursing
Journal:  Diagn Microbiol Infect Dis       Date:  2021-11-17       Impact factor: 2.803

10.  Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19.

Authors:  Jana L Jacobs; Asma Naqvi; Faraaz A Shah; Valerie F Boltz; Mary F Kearney; Bryan J McVerry; Prabir Ray; Caitlin Schaefer; Meghan Fitzpatrick; Barbara Methé; Janet Lee; Alison Morris; John W Mellors; Georgios D Kitsios; William Bain
Journal:  medRxiv       Date:  2022-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.